Navigation Links
BiovaxID?yields 89 percent survival in patients with aggressive non-Hodgkins

Accentia Biopharmaceuticals, Inc. report follow-up data to a Phase 2 trial conducted by the National Cancer Institute (NCI) that shows Biovest's BiovaxID yielded an 89% survival rate in mantle cell lymphoma patients.

The median follow-up was 3.8 years. Historically, patients with this type of lymphoma only have had a 50% chance of surviving 3 years and 20% chance of surviving 5 years. BiovaxID, an investigational personalized anti-cancer vaccine, stimulates the immune system to seek out and destroy tumor cells. The data were published in a recent edition of Nature Medicine (Nat Med.2005; 11(9):986-91).

In this single-arm, open-label Phase 2 clinical study, patients with untreated mantle cell non-Hodgkin's lymphoma (NHL) were administered six cycles of dose-adjusted EPOCH-R, a chemotherapy regimen that includes Rituxan® (rituximab). Of the 26 patients in the study, 23 received vaccinations with BiovaxID commencing at least three months after completing their last chemotherapy and Rituxan treatments. Upon the 46-month (3.8-year) follow-up, the overall survival rate was 89%. This study showed that, despite an almost complete depletion of normal B-cell lymphocytes due to EPOCH-R therapy, BiovaxID did induce anti-tumor T-cell lymphocyte responses in most patients. Depletion of normal B-cell lymphocytes is a consequence of the combination of chemotherapy and Rituxan, but not of BiovaxID therapy. Thus, "it is justifiable to administer vaccines in the setting of B-cell depletion, but vaccine boosts after B-cell recovery may be necessary for optimal humoral responses," concluded the investigators.

Lymphocytes are a type of white blood cell. There are two types of lymphocytes: B-cell lymphocytes, which produce antibodies ("humoral" immunity) in response to immune stimulation; and T-cell lymphocytes, which mediate cell responses to immune stimulation ("cellular" immunity). B-cell lymphocytes can undergo malignant transformation to become non-Hogkins
'"/>

Source:The Investor Relations Group


Page: 1 2

Related biology news :

1. Hunger in America rises by 43 percent over last five years
2. Method slashes quantum dot costs by 80 percent
3. Hepatitis B accounts for 40 percent of missing Asian women
4. Vaccine provides 100 percent protection against avian flu virus in animal study
5. Oceans are 70 percent shark free
6. St. Jude projects 90 percent cure rate for ALL
7. Biofuels can replace about 30 percent of fuel needs with significant research and policy effort
8. Psychotropic drug prescriptions for teens surge 250 percent over 7 year period
9. Just the expectation of a mirthful laughter experience boosts endorphins 27 percent, HGH 87 percent
10. Septum keeps neurons in synch, can reduce epileptic seizures by 90 percent
11. One therapeutic dose of radiation causes 30 percent spongy bone loss in mice
Post Your Comments:
(Date:12/22/2014)... , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... Apollo Robbins for the 2015 International CES debut of ... Robbins will be at the NXT-ID booth January 6th ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... The North American perimeter security market is ... to 2019. Although the U.S. market holds a larger share ...
(Date:12/17/2014)... 15, 2014 The Defense Logistics Agency is insourcing ... prevent counterfeit microcircuits from entering into its supply chain. ... microcircuit anti-counterfeit initiative dubbed DNA marking. The capability will ... reliability throughout the supply chain. The new quality control ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... Leicester and University of California Los Angeles (UCLA) have ... in the body. They have filed two patents ... catalyst for lowering levels of ,bad, cholesterol. Two ... of the regulation of low-density lipoprotein (LDL) or "bad" ...
... have created a scientifically rigorous analogy that shows the similarities ... structure of a melody, proving that the structure of each ... The step-by-step comparison begins with the primary building blocks ... wave and moves up to the level of a ...
... magnetic resonance imaging measures were associated with prognostic ... imaging for prediction of disease prognosis and stratification ... data presented at the 2011 CTRC-AACR San Antonio ... "Breast cancers are heterogeneous, and different subtypes of ...
Cached Biology News:New advance announced in reducing 'bad' cholesterol 2Researchers link patterns seen in spider silk, melodies 2Researchers link patterns seen in spider silk, melodies 3MRI may be noninvasive method to measure breast cancer prognosis 2
(Date:1/23/2015)... Jan. 23, 2015  Array BioPharma Inc. (NASDAQ: ... definitive agreement with Novartis Pharma AG to acquire worldwide ... Phase 3 development.  This agreement is conditional on the closing ... on April 22, 2014, which are expected to close in ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 GEA Niro ... table top laboratory homogenizer, the PandaPLUS 2000, which is ... nanoemulsions , and cell disruption . This compact ... products, fruit juices, liquid food, food additives and ingredients ...
(Date:1/22/2015)... / Rootstown, OH (PRWEB) January 22, 2015 ... platform, announced today that it has received AOAC-PTM Certifications for ... O1O3, O111, O121, and O145; collectively referred to as STEC ... O157, at 1 colony forming unit (cfu) per 325 g ...
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... A/S Summons Annual General Meeting Summary: Genmab ... COPENHAGEN, Denmark, April 7 Genmab A/S (OMX:,GEN) summon the ... CEST at the Radisson SAS Scandinavia Hotel, Amager Boulevard 70, ... Board of Directors on the Company,s activities during,the year., ...
... contains two different types of components: magnetic components, which ... operations. A University of Missouri researcher, as part of ... two functions in a single hybrid material. This new ... functions and is expected to permit the design of ...
... Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... today that the first New Zealand patient,was treated ... in December 2007. A second patient was treated ... first drug-eluting stent for peripheral,arterial disease (PAD) and ...
Cached Biology Technology:Genmab A/S - Notice to Convene Annual General Meeting 2Genmab A/S - Notice to Convene Annual General Meeting 3Genmab A/S - Notice to Convene Annual General Meeting 4Genmab A/S - Notice to Convene Annual General Meeting 5Genmab A/S - Notice to Convene Annual General Meeting 6Genmab A/S - Notice to Convene Annual General Meeting 7Hybrid computer materials may lead to faster, cheaper technology 2Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 2Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 3Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 4
... This depletion cocktail is tailored ... cells from suspensions of non-human ... are separated using the StemSep ... selection system. The CD4+ T ...
... uses the Adept CE 4100 high pressure dual ... dual wavelength detector for added flexibility. ... software and interface unit, CE 4901., The CE ... also be used with Windows 98 and 2000, ...
Anti 4-hydroxy-2-hexenal (4-HHE) Monoclonal Antibody (HNEJ-2)...
Liquid. PBS containing 10 mM NaN 3 . AVOID FREEZE/THAW CYCLES. Recognizes α1, 2, 3, 5, 6 and 7 subunits of 20S proteasome. ...
Biology Products: